CERTIFICATE OF EXCELLENT SERVICE
University of Malaya, 2022 (University)
Expert Panel: Doctor in the House: The Haze and Your Health
BFM 89.9 , 2019 (National)
CERTIFICATE OF EXCELLENT SERVICE
University of Malaya, 2019 (University)
BEST LECTURER AWARD (CLINICAL)
FACULTY OF MEDICINE, 2018 (University)
Specialty Certificate in Respiratory Medicine (SCE, RCP & BTS UK)
Royal College of Physician (UK) & British Thoracic Society, 2017 (International)
Dean's List Award
Faculty of Medicine, University of Malaya , 2005 (University)

1. EGFR mutation positive NSCLC: Mechanistic and clinical considerations for choosing tyrosine kinase inhibitors (TKI). , International Conference on Clinical And Health Sciences 2017 , The institute of Science, Technology and Development Studies (International) (01 Nov 2017 - 01 Nov 2017)
2. Crizotinib as 1st line therapy in patients with ALK mutation positive NSCLC patients, Brain metastasis in ALK mutation positive NSCLC patients, Pfizer Malaysia (Others) (22 Nov 2016 - 22 Nov 2016)
3. Ultibro Breezhaler : A proven treatment for non-exacerbating and exacerbating COPD patients, A closer look into dual-bronchodilation, Novartis Malaysia (Others) (03 Nov 2016 - 03 Nov 2016)
4. Role of the pulmonologist in the management of lung cancer, Integrated Lung Cancer Management in a Tertiary Setting (ILLUMINATE), AstraZeneca Malaysia (National) (08 Oct 2016 - 08 Oct 2016)
5. Impact of an Extra-fine combination on symptom control of obstructive airway disease, Small Airways in Obstructive Lung Diseases, Orient Europharma (National) (11 Aug 2016 - 11 Aug 2016)
6. The role of Gefitnib in the management of NSCLC , Personalized medicine for NSCLC , Astra Zeneca (University) (05 Aug 2016 - 05 Aug 2016)
7. The role of Gefitinib in the treatment of NSCLC, Personalised medicine for Non-small cell Lung Carcinoma (NSCLC), AstraZeneca Malaysia (Others) (05 Aug 2016 - 05 Aug 2016)
8. Poorly controlled bronchial asthma , Respiratory peer-to-peer case scientific exchange meeting , Astra Zeneca (National) (18 May 2016 - 18 May 2016)
9. Dual- bronchodilation : A new treatment option for COPD patients , COPD workshop , Novartis (University) (01 Dec 2015 - 01 Dec 2015)
10. Multidisciplinary management of EGFR mutation positive NSCLC patient , Lung cancer expert forum , Roche Malaysia (National) (31 Oct 2015 - 31 Oct 2015)
11. Cutaneous side effects of tyrosine kinase inhibitors , Discussions on the management of EGFR mutation positive NSCLC , Roche Malaysia (National) (28 Jun 2014 - 28 Jun 2014)

1. (2022) Respiratory Exit Viva Examination December 2022 (Revec), National, (Internal Examiner)
2. (2022) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
3. (2022) Characterization of The Fatty Acid Metabolism-Related Genes in Lung Adenocarcinoma to Guide Clinical Therapy, International, (Reviewer)
4. (2022) Reviewer for Frontiers in Medicine, International, (Reviewer)
5. (2022) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
6. (2022) Reviewer for Journal of Clinical Medicine, International, (Reviewer)
7. (2022) Reviewer for International Journal of General Medicine, International, (Reviewer)
8. (2022) Reviewer for International Journal of General Medicine, International, (Reviewer)
9. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
10. (2022) Reviewer for Cancer Management and Research, International, (Reviewer)
11. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
12. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
13. (2022) Reviewer for Cancer Management and Research, International, (Reviewer)
14. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
15. (2022) Reviewer for International Journal of General Medicine, International, (Reviewer)
16. (2022) Reviewer for Drug Design Developement and Therapy, International, (Reviewer)
17. (2022) Reviewer for Life-Basel, International, (Reviewer)
18. (2022) Reviewer for Future Oncology, International, (Reviewer)
19. (2022) Reviewer for Pharmacogenomics & Personalized Medicine, International, (Reviewer)
20. (2022) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
21. (2022) Reviewer for Journal of Personalized Medicine, International, (Reviewer)
22. (2022) Reviewer for Journal of Inflammation Research, International, (Reviewer)
23. (2021) Reviewer for International Journal of General Medicine, International, (Reviewer)
24. (2021) Reviewer for Npj Primary Care Respiratory Medicine, International, (Reviewer)
25. (2021) Reviewer for Lung Cancer: Targets and Therapy, International, (Reviewer)
26. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
27. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
28. (2021) Reviewer for International Medical Case Reports Journal, International, (Reviewer)
29. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
30. (2021) Reviewer for Lung Cancer: Targets and Therapy, International, (Reviewer)
31. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
32. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
33. (2021) Reviewer for Lung Cancer: Targets and Therapy, International, (Reviewer)
34. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
35. (2021) Reviewer for Scientific Reports, International, (Reviewer)
36. (2021) Reviewer for Discover Oncology, International, (Reviewer)
37. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
38. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
39. (2021) Reviewer for Cancer Management and Research, International, (Reviewer)
40. (2021) Reviewer for Neurology Asia, International, (Reviewer)
41. (2021) Reviewer for Therapeutic Advances in Respiratory Disease, International, (Reviewer)
42. (2021) Reviewer for Oncotargets and Therapy, International, (Reviewer)
43. (2021) Reviewer for International Journal of General Medicine, International, (Reviewer)
44. (2021) Deputy Group Leader for Malaysian Thoracic Society Special Interest Group for Lung Cancer, National, (Expert Advisor)
45. (2019) Department of Medicine Coordinator for UMMP 3.2, UMMP MERDU, National
46. (2021) Moderator: Antimicrobial Resistance in Southeast Asia and Management of Bacterial Infection in Covid, National, (Panelist/Moderator)
47. (2021) Speaker: Managing Respiratory Disorders in The New Norm 2.0, National, (Panelist/Moderator)
48. (2021) Speaker: Interstitial Lung Disease Masterclass, National, (Panelist/Moderator)
49. (2021) Speaker: Introduction of Liquid Biopsies and Emerging Biomarkers for Immune Checkpoint Inhibitor Therapy, National, (Panelist/Moderator)
50. (2021) Speaker: from Evidence to Clinical Practice: Optimizing Treatment for Egfr M+ Nsclc, National, (Panelist/Moderator)
51. (2021) Moderator: Managing Respiratory Disorders in The New Norm, National, (Panelist/Moderator)
52. (2021) Speaker : Influenza - a Real Threat to Older Adults Amid Covid-19, National, (Panelist/Moderator)
53. (2023) Academic Advisor Mmed (Mgf190012), University, (Mentor)
54. (2021) Academic Advisor Mmed (Mgf 120028), University, (Mentor)

WoS
1. How, Soon Hin; Liam, Chong Kin; Abidin, Muhammad Adil Zainal; Hasbullah, Harissa H.; Tho, Lye Mun; Ho, Gwo Fuang; Nor, Ibtisam Muhamad; Pang, Yong Kek; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Ariffin, Roziana; Samsudin, Azlina; Omar, Azza; Tan, Sin Nee; Ong, Choo Khoon; Soon, Sing Yang; Poh, Mau Ern (2022). Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia, CANCER MANAGEMENT AND RESEARCH. 14(), 1995-2005. doi:10.2147/CMAR.S364713
2. How, Soon Hin; Tho, Lye Mun; Liam, Chong Kin; Hasbullah, Harissa H.; Ho, Gwo Fuang; Nor, Ibtisam Muhammad; Poh, Mau Ern; Ho, Kean Fatt; Thiagarajan, Muthukkumaran; Samsudin, Azlina; Omar, Azza; Ong, Choo Khoon; Pang, Yong Kek; Soon, Sing Yang (2022). Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country, THORACIC CANCER. (), . doi:10.1111/1759-7714.14442
3. Narayana, J.; Tiew, P.; Ang, Y.; Quek, M.; Ko, F. W.; Lim, A.; Poh, M.; Jaggi, T.; Xu, H.; Koh, M.; Low, T.; Hassan, T.; Ong, T.; Keir, H.; Tee, A.; Abisheganaden, J.; Aliberti, S.; Blasi, F.; Chalmers, J. D.; Chew, F.; Tsaneva-Atanasova, K.; Chotirmall, S. H. (2022). Topological Data Analysis (TDA) of Allergic Sensitization in Bronchiectasis and COPD, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 205(),
4. Tiew, Pei Yee; Lim, Albert Yick Hou; Keir, Holly R.; Dicker, Alison J.; Mac Aogain, Micheal; Pang, Sze Lei; Low, Teck Boon; Hassan, Tidi Maharani; Poh, Mau Ern; Xu, Huiying; Ong, Thun How; Koh, Mariko Siyue; Abisheganaden, John Arputhan; Tee, Augustine; Chew, Fook Tim; Chalmers, James D.; Chotirmall, Sanjay H. (2022). High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap, CHEST. 161(1), 40-53. doi:10.1016/j.chest.2021.07.2165
5. Zhang, Chuanfen; Wang, Chunmei; Yang, Zhenyu; Bai, Yuquan; Shukuya, Takehito; Poh, Mau-Ern; Ekman, Simon; Li, Jian; Xu, Yuyang; Deng, Senyi (2022). Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance, TRANSLATIONAL LUNG CANCER RESEARCH. (), . doi:10.21037/tlcr-22-318
6. Mac Aogain, M., Narayana, J. K., Tiew, P. Y., Ali, N., Yong, V. F. L., Jaggi, T. K., . . . Chotirmall, S. H. (2021). Integrative microbiomics in bronchiectasis exacerbations. Nature Medicine, 27(4), 32. doi: 10.1038/s41591-021-01289-7
7. Mac Aogain, Micheal; Ivan, Fransiskus Xaverius; Jaggi, Tavleen; Keir, Holly R.; Dicker, Alison J.; Hou, Albert Lim Yick; Poh, Mau Ern; Oriano, Martina; Koh, Mariko Siyue; How, Ong Thun; Tee, Augustine; Low, Teck Boon; Abisheganaden, John Arputhan; Aliberti, Stefano; Blasi, Francesco; Chalmers, James D.; Chotirmall, Sanjay H. (2021). The bronchiectasis 'bacteriophagome', EUROPEAN RESPIRATORY JOURNAL. 58(), . doi:10.1183/13993003.congress-2021.OA1306
8. Pang, Y. K., Ismail, A. I., Chan, Y. K. F., Cheong, A., Chong, Y. M., Doshi, P., . . . Taurel, A. F. (2021). Influenza in Malaysian adult patients hospitalized with community-acquired pneumonia, acute exacerbation of chronic obstructive pulmonary disease or asthma: a multicenter, active surveillance study. Bmc Infectious Diseases, 21(1), 14. doi: 10.1186/s12879-021-06360-9
9. Poh, M. E., Ampikaipakan, S., Liam, C. K., Chai, C. S., Ramanaidoo, D., & Mydin, H. H. (2021). Management of Asthma Exacerbations in Southeast Asian Tertiary Care. Journal of Asthma and Allergy, 14, 629-640. doi: 10.2147/jaa.s309143
10. Tian, Y., Li, P. W., Xiao, Z. H., Zhou, J., Xue, X., Jiang, N., . . . Zhao, X. G. (2021). Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/ beta-catenin signaling pathway in taxol-resistant human lung adenocarcinoma. Translational Lung Cancer Research, 10(2), 1007-+. doi: 10.21037/tlcr-21-145
11. Chai, C. S., Liam, C. K., Poh, M. E., Ong, D. B. L., Pang, Y. K., Cheah, P. L., . . . Alip, A. (2020). Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Cancer Management and Research, 12, 5439-5450. doi: 10.2147/cmar.s253760
12. Liam, C. K., Liam, Y. S., Poh, M. E., & Wong, C. K. (2020). Accuracy of lung cancer staging in the multidisciplinary team setting. Translational Lung Cancer Research, 9(4), 1654-1666. doi: 10.21037/tlcr.2019.11.28
13. Tiew, P. Y., Ko, F. W. S., Narayana, J. K., Poh, M. E., Xu, H. Y., Neo, H. Y., . . . Chotirmall, S. H. (2020). "High-Risk" Clinical and Inflammatory Clusters in COPD of Chinese Descent. Chest, 158(1), 145-156. doi: 10.1016/j.chest.2020.01.043
14. Tiew, P. Y., San Ko, F. W., Pang, S. L., Matta, S. A., Sio, Y. Y., Poh, M. E., . . . Chotirmall, S. H. (2020). Environmental fungal sensitisation associates with poorer clinical outcomes in COPD. European Respiratory Journal, 56(2), 13. doi: 10.1183/13993003.00418-2020
15. Poh, M. E., Liam, C. K., Mun, K. S., Chai, C. S., Wong, C. K., Tan, J. L., . . . Chin, K. K. (2019). Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy. Thoracic Cancer, 10(9), 1841-1845. doi: 10.1111/1759-7714.13156
16. Poh, M. E., Liam, C. K., Rajadurai, P., Chai, C. S. (2018). Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. Journal of Thoracic Disease, 10(7), E560-E563. doi:10.21037/jtd.2018.06.122
17. Poh, M. E., Ng, W. L., Liam, C. K., Ramli, N. M., Hashim, S. (2018). Bilateral pulmonary sequestrations mimicking advanced lung malignancy. Journal of Thoracic Disease, 10(9), E710-E713. doi:10.21037/jtd.2018.09.12
18. Poh, M. E., Liam, C. K., Ng, K. P., Tan, R. X. (2014). Mycobacterium Brisbanense Species Nova Isolated From a Patient With Chronic Cavitary Lung Infection, Chest. 145(4), 858-8600012-3692.
Others
1. Liam CK, Poh ME, Liam YS (2019). Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation. J Thorac Dis 2019; 11: S1847-S1851
2. Chai CS, Liam CK, Poh ME et al.(2017). Epidermal growth factor receptor mutation in newly diagnosed lung adenocarcinoma. J Respir Med Lung Dis; 2(2): 1016.
3. Liam CK, Pang YK and Poh ME. EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology. 2014; 9(9):e70-1
4. Poh ME, Liam CK, Tan JL, et al. Acrometastasis from an epidermal- growth-factor-receptor (EGFR) mutation-positive lung adenocarcinoma. Cancer Treatment Communications. 2014; Volume 2 (Issues 2-3):21-23
5. Liam CK, Poh ME, Pang YK et al. Advanced right lung adenocarcinoma with ipsilateral breast metastasis. Respirology Case Report. 2013; 1(1):20- 22
6. Poh ME, Liam CK, Pang YK, et al. Endobronchial metastases from resected renal cell carcinoma causing total lung collapse. Respirology Case Report. 2013; 1(2):26-7
Sim BLH, Nissapatorn V, Poh ME, et al. Toxoplasmosis: a silent opportunistic diseases in HIV/AIDS patients. Research Journal of Parasitology. 2007; 2(1):23-31
7. Poh ME, Liam CK, Chai CS, Pang YK, Tan JL. Abstract ID 240 Outcome of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and first-line chemotherapy in advanced lung adenocarcinoma. Respirology 2015; 20(S3): 87-103 - Extended Abstract

1. 2020 - 2023, RU Geran - Fakulti Program
Lignosus Rhinocerus Tm02 As An Immunomodulatory Agent For The Treatment Of Uncontrolled Asthma And Allergic Rhinitis: A Randomised, Double Blind, Placebo-control Study ( Principal Investigator(PI))
2. 2020 - 2021, Hospital Taping
One-Year Surveillance Study Of Influenza and Respiratory Syncytial Virus Infections Among Hospitalised Older Adults (>=65 Years) in Malaysia ( Co-Researcher)
3. 2018 - 2025, Private Funding
CACZ885T2301: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) ( Consultant)
4. 2017 - 2022, Private Funding
MK-3475-654 : A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1 ( Consultant)
5. 2018 - 2021, Private Funding
MK-7264-030: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030) ( Consultant)
6. 2018 - 2021, Private Funding
HM-EMSI-301: A multi-national, randomized, multi-center, active controlled, open- label Phase III study evaluating the efficacy of olmutinib versus platinum doublet chemotherapy in patients with T790M mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on one prior epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment ( Consultant)
7. 2018 - 2020, Private Funding
64041575MPN2001: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Adult Subjects Infected With Human Metapneumovirus ( Consultant)
8. 2015 - 2019, Private Funding
Bevacizumab Biosimilar Study BI 695502-A multicentre, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin plus chemotherapy in patients with advanced Non-squamous Non-small cell lung cancer. ( Consultant)
9. 2017 - 2019, External Grant from Nanyang Techonology University Singapore
Define clinical, microbiological and inflammatory phenotype of Asian COPD ( Principal Investigator(PI))
10. 2016 - 2018, Private Funding
FLAURA (NCT 02296125)- A randomized, double-blind, phase III study comparing the effcicacy and safety of AZD9291, a novel EGFR-TKI, versus gefinitib or erlotinib in treatment-na ve patients with advanced non-small cell lung cancer and an EGFR-TKI sensitizing mutation. ( Consultant)
11. 2016 - 2018, Private Funding
MK3475-042/KEYNOTE-042- A randomized, open label, Phase III study of Overall Survival comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Na ve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer ( Consultant)
12. 2016 - 2018, Private Funding
D419AC00003: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NEPTUNE) ( Consultant)